This article is available online at http://www.jlr.org lipoproteins. Agonist-induced lipolysis is mediated by consecutive activation of the adenylate cyclase (AC), resulting in cAMP production and protein kinase A (PKA) activation by cAMP, followed by PKA-induced phosphorylation of hormone-sensitive lipase (HSL) at three serine residues (563, 659, and 660), resulting in its activation and translocation from the cytosol to the lipid-droplet surface. Concomitant with HSL phosphorylation, the phosphorylation of perilipin by PKA at multiple sites (S81, S222, S276, and S517) results in a dynamic restructuring of the lipid-droplet surface, in facilitating the translocation of phosphorylated HSL to the lipid droplet, and in activating its hydrolyzing activity. Perilipin phosphorylation by PKA further results in releasing CGI-58 from the lipid droplet, in its association with adipose triacylglycerol lipase (ATGL), and in activating its lipolytic activity. Activated ATGL, HSL, and monoglyceride lipase may act now consecutively in hydrolyzing adipose triacyglycerols to diacylglycerol, monoacylglycerol, and fi nally to free glycerol and LCFA. Agonist-induced cAMP and lipolysis is restrained by insulin due to cAMP hydrolysis by insulin-activated phosphodiesterase3B (PDE3B) ( 2 ), combined with insulin-induced reesterifi cation of LCFA into adipose fat (reviewed in Ref.
vine serum (Biological Industries), 2.0 mM L-glutamine, 100 U/ml penicillin, 0.1 mg/ml streptomycin, and 0.25 µg/ml amphotericin B (Biological Industries). When reaching 60-70% confl uence, the cells were further cultured to confl uence in 12-well plates (Cell Star) in medium A. For conversion to adipocytes, two-day postconfl uent cultures were further cultured for three days in medium B, where the 10% bovine serum of medium A was replaced by 10% fetal calf serum (FCS) (Biological Industries), supplemented with 2.5 U/ml human insulin (Homulin, Eli Lilly), 4 g/ml dexamethasone (Merck), and 0.5 mM 1-methyl-3-isobutyl-1-methylxantine (IBMX). Cells were further cultured for two days in the presence of 2.5 U/ml human insulin, followed by 7-10 days with insulin-free medium, being replaced with fresh medium every two days. For measuring lipolysis, 3T3-L1-differentiated adipocytes were cultured in DMEM medium supplemented with 10% FCS, in the presence of additions as indicated. One hour prior to glycerol measurement, the culture medium was replaced with Phenol Red-free DMEM medium, supplemented with 2% fatty-acid-free BSA (Roche) and additions as indicated. Glycerol release (arbitrary units) into the medium was determined by using free glycerol reagent kit (#F6428, Sigma-Aldrich). Basal glycerol release of 3T3-L1 cells cultured in 12-well plates were in the range of 0.85-2.1 µg/well.
COS-1 and HeLa cells were cultured in 12-or 24-well plates in DMEM, 1.0 mM glutamine, 100 U penicillin/ml, and 0.1 mg streptomycin/ml medium, supplemented with 10% FCS. All cultures were maintained at 37°C in a humidifi ed atmosphere of 7% CO 2 in air.
Cell extracts
3T3L-1 adipocytes were washed with cold phosphate-buffered saline (PBS) and extracted with cold 150 l lysis buffer consisting of 10 mM Tris buffer (pH 8.0), 150 mM NaCl, 1% Triton X-100 (w/w), 0.24 mM sodium orthovanadate, 60 mM sodium fl uoride, 60 mM octyl ␤ -D-glucopyranoside (#O-8001, Sigma-Aldrich), 1.0 mM phenylmethylsulphonylfl uoride (PMSF), 0.1 g/ml okadaic acid, 40 nM bis-peroxo(1,10 phenanthroline) oxovanadate(V) (bpV(phen), and 1 l/ml protease inhibitor mix (Sigma-Aldrich). The lysate was immediately sonicated on ice for 5 s using a tip sonicator (Ultrasonics), then further incubated in lysis buffer for 30 min at 4°C, and then centrifuged at 23,000 g for 15 min at 4°C. The aqueous phase, in between the cell precipitate and the fl oating upper lipid phase, was collected and stored at Ϫ 70°C.
Extracts of COS-1 or HeLa cells were prepared by sonicating the cells in 3 vol of lysis buffer, followed by further incubation in lysis buffer for 30 min at 4°C. Lysates were cleared by centrifugation at 15,000 g for 10 min at 4°C, and the supernatant was kept at Ϫ 70°C.
Protein content of cellular extracts was determined by the BCA protein assay (#23225, Pierce Biotechnology). cAMP 3T3-L1-differentiated adipocytes (cultured in 12-well plates) or COS-1 cells (cultured in 24-well plates) were incubated with additions as indicated. cAMP was determined using an enzyme immunoassay kit (#RPN225, Amersham) according to manufacturer instructions.
Western blot analysis
Samples of 15-45 g protein were resolved by 7-12.5% SDS-PAGE under reducing conditions and were then transferred onto polyvinylidene difl uoride (Millipore) or cellulose nitrate membranes (Schleicher and Schuell). PKA-phosphorylated HSL (P-HSL) and perilipin (P-perilipin) were determined by antiphosphoPKA-concensus site antibodies. Phosphorylated and total protein blots were carried out using the same lysates. Blots were probed with the indicated fi rst antibody, followed by horseradish ( 4, 5 ) . The mode of action of LCFA in suppressing agonistinduced lipolysis still remains to be investigated, being ascribed to product inhibition of HSL by its association with fatty acid-bound aP2 ( 6 ), or alternatively, to futile cycling of LCFA between lipolysis and reesterifi cation ( 7 ) .
MEDICA analogs (8) (9) (10) (11) (12) consist of long-chain methylsubstituted ␣ , -dicarboxylic acids [e.g., HOOC-CH 2 -C( ␤ )(CH 3 ) 2 -(CH 2 ) 10 -C( ␤ )(CH 3 ) 2 -CH 2 -COOH defi ned as MEDICA16/M ␤ ␤ ]. MEDICA analogs are not esterifi ed into lipids, and the methyl substitutions at the ␤ , ␤ ' positions block their ␤ -oxidation. Similar to LCFA, MEDICA analogs may be thioesterifi ed endogenously into their respective monoacyl-CoA thioesters, but CoA-thioesterifi cation of MEDICA analogs does not result in sequestration of CoA and does not limit the CoA-thioesterifi cation of endogenous LCFA or their ␤ -oxidation ( 13 ) . Hence, MEDICA analogs may simulate LCFA effects in the lipolysis context while avoiding its own esterifi cation into adipose fat. Indeed, treatment of animal models of diabesity (e.g., Zucker, cp/cp, db/db, ob/ob) with MEDICA analogs has been reported to result in pronounced decrease in plasma FFA, hepatic glucose and lipoprotein production, with concomitant increase in total body glucose uptake and plasma lipoprotein clearance (9) (10) (11) (12) . In fact, the overall phenotype of MEDICA-treated animal models of diabesity appears to be essentially similar to that of HSL-knockouts ( 14 ) , indicating that inhibition of agonist-induced lipolysis could play a role in total body sensitization to insulin by MEDICA analogs. The present report verifi es the activity of M ␤ ␤ in the context of agonist-induced lipolysis and dissects its mode of action in terms of modulating the AC/ PKA transduction pathway of adipose lipolysis. Our fi ndings may further indicate that synthetic LCFA may serve as insulin mimetics in the lipolysis context, while bypassing the insulin transduction pathway.
EXPERIMENTAL PROCEDURES

Animals
Male Wistar rats weighing 250-275 g and fed standard rodent diet (Teklad 2018) were daily dosed by gavage for fi ve consecutive days with 200 mg M ␤ ␤ /kg body weight in 1% carboxy methyl cellulose (CMC) or with vehicle only, in line with previously reported dose-effi cacy studies (8) (9) (10) (11) (12) . Fasting animals were then implanted with PE50 jugular vein cannula under ketamine/xylazine anesthesia and left to recover for 24 h. On the following day, the animals were dosed with M ␤ ␤ or vehicle, followed 120 min later by single intraperitoneal injection of 10 mg isoproterenol/kg body weight. Blood samples (200 l) were collected in EDTA at time points as indicated, and plasma glycerol levels were determined by using free glycerol reagent kit (#F6428, Sigma-Aldrich). Basal plasma glycerol levels were 0.26 ± 0.8 and 0.17 ± 0.1 mol/ml for CMCand M ␤ ␤ -treated animals, respectively (not signifi cant). Animal care and experimental procedures were in accordance with the accredited animal ethics committee of the Hebrew University.
Cell culture
3T3-L1 preadipocytes were fi rst cultured in 10 cm Falcon plates in medium A, consisting of Dulbecco modifi ed Eagle medium (DMEM) supplemented with 25 mM glucose, 10% boby guest, on October 22, 2017 www.jlr.org
, tunicamycin, thapsigargin, and cholera toxin (CTX) were from Sigma-Aldrich. Pertussis toxin (PTX), MDL 12,330A, and AICAR were from Calbiochem. M ␤ ␤ (99.5% purity) was synthesized as previously described ( 8 ) .
Data analysis
Statistical analysis was performed by one-way repeated measure ANOVA with Student-Newman-Keuls test. When only two groups were compared, signifi cance was analyzed by paired t -test.
RESULTS
Inhibition of isoproterenol-induced lipolysis by M ␤ ␤
Suppression of adipose lipolysis by MEDICA in vivo was studied in Wistar rats treated with M ␤ ␤ and then challenged with a single injection of isoproterenol ( Fig. 1 ) . Isoproterenolinduced glycerol release in vehicle-treated animals resulted in increase in plasma glycerol reaching its Cmax in about 60 min, followed by reverting gradually to basal glycerol levels. Treatment with M ␤ ␤ resulted in shorter time to maximal level (Tmax), lower maximal level (Cmax), and 50% decrease in the total amount of glycerol release, implying inhibition of isoproterenol-induced adipose lipolysis in vivo.
In line with inhibition of adipose lipolysis by M ␤ ␤ in vivo ( Fig. 1 ) and in analogy to natural LCFA in vitro ( 4, 5 ) , isoproterenol-induced lipolysis of 3T3-L1 adipocytes was robustly inhibited by M ␤ ␤ ( Fig. 2A ) , as well as by other MEDICA analogs (not shown). Inhibition by M ␤ ␤ was concentration dependent, with an apparent IC50 of 200 M ( Fig. 2B ) . The µM concentrations of M ␤ ␤ refl ect the high binding affi nity of MEDICA analogs to medium albumin [estimated to be higher than 99%, independent of M ␤ ␤ concentrations in the range of 0-0.9 mM (unpublished results)], resulting in nanomolar concentrations of the free MEDICA acid in the culture medium. Inhibition by M ␤ ␤ was progressive throughout the fi rst 24 h of incubation ( Fig. 2C ), being already evident within the fi rst 2 h. Inhibition of isoproterenol-induced lipolysis by M ␤ ␤ was accompanied by inhibition of isoproterenol-induced phosphorylation of HSL (P-HSL) ( Fig. 2D ) and perilipin (P-perilipin) ( Fig. 2E ) by PKA.
Inhibition of isoproterenol-induced lipolysis by M ␤ ␤ -activated AMPK
We have recently reported that LCFA and their MED-ICA analogs activate AMP-protein kinase (AMPK) through increase in intracellular AMP/ATP ratio by the free LCFA/ MEDICA acid, complemented by activation of LKB1 phosphorylation of AMPK ␣ (Thr172) by the respective CoA monothioester ( 12 ) . AMPK activation by LCFA/MEDICA prompted us to probe the putative role played by AMPK in mediating inhibition of lipolysis by M ␤ ␤ . Inhibition of lipolysis by M ␤ ␤ was compared with that induced by 5-aminoimidazole-4-carboxamide-1-␤ -D-ribofuranoside (AICAR)/ZMP-activated AMPK (16) (17) (18) (19) . AMPK of 3T3-L1 adipocytes was activated by M ␤ ␤ ( Fig. 3A ) or AICAR ( 19 ) (not shown), as verifi ed by the increase in phosphorylation of AMPK(T172) and its downstream P-ACC(S79) peroxidase-labeled second antibody. Bands were analyzed by ImageQuant software (Molecular Devices). Three or more experiments were used in presenting respective histograms.
Transfection
COS-1 cells, cultured in DMEM containing 10% FCS, were transfected with pEGFP-Raf-1 or pEGFP expression plasmids (T. Balla) ( 15 ) using TransIT-LT1 transfection reagent (Mirus Bio). Following 6 h of transfection, the cells were incubated in fresh medium for 18 h to allow for the expression of transfected plasmids, followed by 24 h in the presence of additions as indicated.
Real time PCR
Total RNA was prepared using the TRI reagent (SigmaAldrich). First-strand cDNA used as template was synthesized by reverse transcription using oligo(dT) as primer and the ReverseiTMAX First Strand Kit (ABgene). Raf1, CHOP, and BiP transcripts normalized by tubulin were quantifi ed by real-time PCR (Rotor Gene RG-3000A) using SYBER green MasterMix (Absolute Syber Green ROX Mix, ABgene) and the following primers:
AMPK ␣ 1 silencing by siRNA 3T3-L1 adipocytes, cultured for three to fi ve days after insulin removal, were transiently transfected with a pool of three siRNA oligonucleotides against mouse AMPK ␣ 1 (SC-29674), while scrambled siRNA (SC-37007, Santa Cruz Biotechnology) served as negative control. Briefl y, 7.5 µl of siRNA and 4 µl of transfection reagent (Lipofectamine 2000, Invitrogen) were each diluted with 25 µl of serum-free media (Opti-MEM, Invitrogen), mixed, and further incubated for 20 min at room temperature. The transfection mixture was added drop by drop to each culture well containing 450 µl of serum-free media, reaching fi nal siRNA concentrations of 150 nM. Transfected cells were incubated for 4 h, followed by adding to each well 500 µl of DMEM medium supplemented with 20% FBS. Following incubation for additional 24 h, the medium was replaced by DMEM medium supplemented with 10% FCS. The transfected cells were incubated for 24 h to allow for AMPK ␣ 1 silencing, followed by 24 h in the presence of additions as indicated. Cells were lysed as described above.
MATERIALS
Rabbit polyclonal anti-mouse acetyl-CoA carboxylase (ACC) (#3662), rabbit polyclonal anti-mouse P-ACC(S79) (#3661S), rabbit polyclonal anti-mouse phosphoPKA-concensus site (#9261S), rabbit anti-mouse AMPK (#2532), rabbit anti-mouse P-AMPK(T172) (#2531S), rabbit polyclonal anti-human/mouse eIF2 ␣ (#9722), and P-eIF2 ␣ (S51) (#9721S) antibodies were from Cell Signaling Technology. Rabbit polyclonal anti-mouse Raf1 antibody (#SC-227) was from Santa Cruz Biotechnology. Rabbit polyconal antimouse HSL (#ab-45422) was from Abcam. Rabbit polyclonal anti-mouse perilipin A (#PA1-1051) antibody was from Affi nity BioReagents. Mouse monoclonal anti-␣ -tubulin antibody (#T5168) was from Sigma-Aldrich. Horseradish peroxidase-labeled antimouse secondary antibody was from Jackson ImmunoResearch Laboratories. Forskolin, IBMX, N 4B ) cAMP levels in 3T3-L1 adipocytes as well as in other cell types (e.g., Cos-1, Jurkat, and HeLa). Suppression of isoproterenol-induced cAMP levels by M ␤ ␤ was further pursued in terms of the putative activation of phosphodiesterase3B (PDE3B) and/or inhibition of the adenylate cyclase (AC) ( 1 ). cAMP levels induced by forskolin/IBMXactivated AC ( Fig. 4B ) as well as lipolysis induced by PDE3B inhibition by IBMX ( Fig. 4C ) were both robustly inhibited by M ␤ ␤ , indicating that inhibition by M ␤ ␤ prevailed under conditions of PDE3B inhibition. Also, under conditions of inhibiting the AC by MDL 12,330A ( 22 ), But 2 cAMPinduced lipolysis and 8-bromo-cAMP-induced lipolysis remained unaffected by M ␤ ␤ ( Fig. 4C ) , implying inhibition of cAMP production rather than its degradation by activated PDE3B. Hence, in contrast to insulin, where inhibition of agonist-induced cAMP and lipolysis is due to PDE3B activation, inhibition by M ␤ ␤ may be ascribed to inhibition of the AC activity.
M ␤ ␤ targets upstream of AC were pursued by evaluating fi rst the effect of M ␤ ␤ in the presence of added CTX or product, being already evident within the fi rst 2 h of incubation. Also, similar to M ␤ ␤ ( Fig. 2 ) and in line with previous reports of suppression of lipolysis by activated AMPK (16) (17) (18) , isoproterenol-induced lipolysis ( Fig. 3B ) , P-HSL, and P-perilipin ( Fig. 3C ) were inhibited by AICAR, being abrogated by inhibition of the adenosine kinase by 5 ′ -amino-5 ′ -deoxyadenosine (AMDA) ( 20, 21 ) , implying ZMPactivated AMPK. Inhibition of lipolysis by both AICAR/ ZMP-activated AMPK and M ␤ ␤ -activated AMPK may indicate causal relationship between AMPK activation and inhibition of agonist-induced lipolysis by M ␤ ␤ .
Suppression of isoproterenol-induced cAMP by M ␤ ␤ or AICAR
As HSL and perilipin are both phosphorylated by PKA in response to isoproterenol-induced cAMP (reviewed in Ref. 1 ), inhibition of agonist-induced lipolysis by M ␤ ␤ or AICAR was further pursued by verifying respective cellular cAMP levels. Indeed, inhibition of agonist-induced lipolysis by M ␤ ␤ or AICAR was accompanied by suppression of isoproterenol-induced cAMP levels ( Fig. 4A ) and forskolin/ PTX, which activate the AC by persistent G ␣ s activation or G ␣ i inhibition, respectively ( 23 ) . CTX-induced lipolysis ( Fig.  4C ) as well as CTX-or PTX-induced P-HSL ( Fig. 4D ) were robustly suppressed by M ␤ ␤ , implying inhibition of the AC activity per se, rather than modulation of its upstream G ␣ s M ␤ ␤ still inhibited isoproterenol-induced lipolysis, P-HSL, and P-perilipin in 3T3-L1 cells transfected with Si-AMPK ( Fig. 5C ) , implying an additional AMPK-independent activity of M ␤ ␤ in suppressing Raf1 expression. An AMPKindependent activity of M ␤ ␤ has been further verifi ed in HeLa cells that lack LKB1 and where MEDICA analogs fail to activate AMPK ( 12 ) . Treatment of HeLa cells with M ␤ ␤ resulted in suppressing Raf1 expression (not shown), implying an upstream target for M ␤ ␤ in suppressing Raf1 expression, in addition to AICAR-or M ␤ ␤ -activated AMPK.
UPR activation by M ␤ ␤
LCFA have been reported to induce components of the unfolded protein response (UPR) in a variety of cell lines ( 27, 28 ) , prompting us to search for a possible link between UPR components and suppression of Raf1 expression by M ␤ ␤ . Treatment of 3T3-L1 adipocytes with M ␤ ␤ indeed resulted in induction of the UPR markers
Raf1 suppression by M ␤ ␤ and AICAR
Because Raf1 of the mitogen-activated protein kinase (MAPK) transduction pathway interacts with and activates the AC ( 24-26 ), suppression of the AC/cAMP/PKA transduction pathway by M ␤ ␤ or AICAR was further pursued by evaluating Raf1 expression. Treating 3T3-L1 cells as well as other cell types (e.g., COS-1, Jurkat) with M ␤ ␤ or AICAR resulted in suppressing Raf1 protein levels ( Fig. 5A ). Raf1 suppression by AICAR was abrogated by AMDA ( Fig. 5A ), implying causal relationship between ZMP-activated AMPK and Raf1 levels. Furthermore, overexpression of Raf1 resulted in abrogating suppression of cAMP levels by M ␤ ␤ ( Fig.  5B ), implying causal relationship between Raf1 suppression and inhibition of isoproterenol-induced cAMP by M ␤ ␤ .
The role played by putative AMPK-independent upstream targets of M ␤ ␤ in suppressing Raf1 expression was verifi ed in 3T3-L1 adipocytes transfected with Si-AMPK, thereby resulting in about 85% suppression of P-ACC(S79) . 
DISCUSSION
Since the 1970s, it has been known that agonist-induced adipose lipolysis is inhibited by the LCFA generated through lipolysis and that it requires constant removal of free nonesterifi ed fatty acids by their binding to medium albumin or by frequent medium replacement ( 4, 5 ) . However, the mode of inhibition of agonist-induced lipolysis by its LCFA end product remained to be resolved. Moreover, no attempts were made to exploit the inhibitory effi cacy of CHOP and BiP transcripts, as well as P-eIF2 ␣ (S51) ( Fig. 6A ) , to an extent similar to that induced by thapsigargin or tunicamycin. Also, suppression of Raf1 expression ( Fig.  6B ) , isoproterenol-induced P-HSL ( Fig. 6C ) , and agonistinduced glycerol release ( Fig. 6D ) by M ␤ ␤ were partly rescued by abrogating UPR by the chemical chaperone phenylbutyric acid (PBA) ( 29 ) , pointing to a causal linkage between M ␤ ␤ -induced UPR and suppression of isoproterenol-induced lipolysis by M ␤ ␤ . In contrast to M ␤ ␤ , AICAR/ZMP failed to induce the UPR marker CHOP or BiP ( Fig. 6A ) , and PBA failed to abrogate suppression of Raf1 by AICAR ( Fig. 6E ) , implying that suppression of isoproterenol-induced lipolysis by AICAR/ZMP may M ␤ ␤ may imply that inhibition of agonist-induced lipolysis by M ␤ ␤ may partly be accounted for by the AMPK/Raf1 cross-talk exemplifi ed by AICAR. The mode of suppression Raf1 expression by activated AMPK still remains to be investigated. ii ) Failure of Si-AMPK to abrogate suppression of agonist-induced lipolysis by M ␤ ␤ ( Fig. 5C ) points to an additional M ␤ ␤ target involved in suppressing lipolysis, independent of M ␤ ␤ -activated AMPK. Indeed, suppression of Raf1 expression, isoproterenol-induced P-HSL, and lipolysis by M ␤ ␤ was partly abrogated by the PBA chaperone ( Fig. 6 ) , indicating causal linkage between M ␤ ␤ -induced UPR components, suppression of Raf1, and inhibition of agonist-induced lipolysis. Preliminary profi ling of UPR markers induced by MEDICA analogs in cell lines and in vivo has indicated a specifi c profi le of UPR markers rather than a canonical response (Hertz et al., unpublished) . Lack of UPR activation by AICAR may indicate that induction of UPR components by M ␤ ␤ is not accounted for by AMPK activation. iii ) Suppression of isoproterenol-induced P-HSL, P-perilipin , and lipolysis by M ␤ ␤ or AICAR was accompanied by decrease in cellular cAMP and was abrogated by added But 2 cAMP ( Fig. 4 ) , implying causal linkage between suppression of cellular cAMP levels and suppression of agonist-induced lipolysis by M ␤ ␤ or AICAR. iv ) Suppression of cellular cAMP by M ␤ ␤ was abrogated in cells overexpressing Raf1 ( Fig. 5B ) , implying causal linkage between Raf1 activity and cellular cAMP content. v ) In light of PDE3B inhibition by IBMX, suppression of IBMXinduced lipolysis by M ␤ ␤ ( Fig. 4 ) implies inhibition of cAMP production rather than its hydrolysis by PDE activation. Similarly, lipolysis induced by 8-bromo-cAMP, under conditions of inhibiting the adenylate cyclase by MDL ( Fig. 4C ) , remained unaffected by M ␤ ␤ , further implying inhibition of cAMP production rather than its degradation. vi ) The putative suppression of CGI-58/ATGL activity by M ␤ ␤ due to suppression of perilipin phosphorylation still remains to be verifi ed.
The fi ndings reported here confi rm previous studies in which constitutive-active AMPK was reported to suppress isoproterenol-induced lipolysis ( 17 ) . However, our fi ndings do not conform to other studies using AMPK inhibitors [e.g., DN-AMPK ( 33 ) and compound C ( 34 )] or to those in which AMPK was claimed to be required for promoting lipolysis. Also, our fi ndings may account for the mode of activation of AMPK by agonist-induced lipolysis ( 7, (33) (34) (35) ( Fig. 3A ) , previously ascribed to cAMPactivated PKA or Epac1 ( 35 ) or, alternatively, to PKAindependent increase in intracellular AMP/ATP ratio due to ATP-consuming futile cycling of LCFA between lipolysis and reesterifi cation ( 7 ) . Thus, isoproterenol-induced AMPK may be ascribed to direct AMPK activation by the free LCFA generated during lipolysis ( 12 ) . The primary role played by the acyl-CoA in activating AMPK ( 12 ) may account for the reported abrogation of isoproterenol-induced AMPK upon inhibiting the LCFA-CoA synthase by triacsin C ( 7 ).
Our fi ndings may indicate that synthetic LCFA analogs may inhibit lipolysis while bypassing the insulin transduction pathway. The effi cacy of M ␤ ␤ in suppressing of Raf1 expression by M ␤ ␤ is proposed to be accounted for by both, M ␤ ␤ -activated AMPK, complemented by M ␤ ␤ -induced UPR components. M ␤ ␤ -activated AMPK is proposed to account for the immediate activity of M ␤ ␤ in suppressing Raf1 cellular content, while suppression of Raf1 expression by M ␤ ␤ -induced UPR may account for the progressive activity of M ␤ ␤ in suppressing agonist-induced lipolysis ( Fig. 2C ) . Suppression of Raf1 by M ␤ ␤ is proposed to result in inhibition of agonist-induced lipolysis due to inhibition of the adenylate cyclase activity, followed by decrease in agonist-induced cAMP and PKA-induced P-HSL and P-perilipin. It is noteworthy that perilipin phosphorylation by PKA may result in both, facilitating HSL contact with the lipid droplet as well as dissociation of CGI-58 from P-perlipin followed by its activation of ATGL ( 30 ) . In contrast to M ␤ ␤ , inhibition of agonist-induced lipolysis by AICAR is proposed to be solely accounted for by suppression of Raf1 expression by ZMP-activated AMPK. As MEDICA analogs simulate the characteristics of LCFA in terms of AMPK activation ( 12 ) and in inducing UPR ( 27, 28 ) , we may assume that the mode of action proposed for MEDICA may account, at least partially, for inhibition of agonist-induced lipolysis by LCFA ( 4, 5 ) . In light of AMPK activation by metformin or octanoate ( 31, 32 ) , the proposed transduction pathway may also offer a mode of action for the recently reported activity of metformin ( 31 ) or octanoate ( 32 ) in suppressing isoproterenol-induced lipolysis in primary rat adipocytes or 3T3-L1 adipocytes, respectively.
The proposed mode of action outlined in Fig. 7 is supported by the following fi ndings: i ) Raf1 suppression by AICAR was abrogated by AMDA ( Fig. 5A ) , implying ZMPactivated AMPK. Raf1 suppression and inhibition of agonistinduced lipolysis by AICAR was not accompanied by induction of UPR components ( Fig. 6A ) , and it was not abrogated by the PBA chaperone ( Fig. 6E ) , implying a UPR-independent AICAR activity. AMPK activation by Fig. 7 . Suppression of Raf1 expression by LCFA/MEDICA is proposed to be accounted for by activated AMPK, complemented by induced UPR. Raf1 suppression by AICAR is proposed to be solely accounted for by ZMP-activated AMPK. Suppression of Raf1 expression results in inhibition of the adenylate cyclase (AC) activity, followed by decrease in agonist-induced cAMP and in cAMPinduced PKA. Suppression of PKA-induced P-HSL and P-perilipin, followed by suppression of P-perlipin-induced CGI-58/ATGL, results in overall inhibition of agonist-induced lipolysis.
by guest, on October 22, 2017 www.jlr.org Downloaded from agonist-induced lipolysis may add to previously reported insulin-sensitizing and hypolipidemic activities of MEDICA analogs in suppressing hepatic glucose and lipoprotein production, and in enhancing total body glucose uptake and plasma lipoprotein clearance in animal models of diabesity (8) (9) (10) (11) (12) .
